NBPF9: A Potential Drug Target and Biomarker (G400818)

Target Name: NBPF9

NCBI ID: G400818

NBPF9

NBPF9: A Potential Drug Target and Biomarker

Non-Binary Promises Foundation (NBPF) is a non-profit organization dedicated to supporting and promoting the development of novel biotherapeutic compounds, with a focus on the discovery and development of small molecules that target N-linked glycans (N-glycans). One of their research targets is NBPF9, a potential drug target and biomarker that has garnered significant interest in the scientific community. In this article, we will explore the story behind NBPF9 and its potential impact on the pharmaceutical industry.

The quest to discover new drug targets is a journey that began with the identification of potential N-glycans. N-glycans are a type of sugar molecule that are attached to various proteins found throughout the body. They play a crucial role in cellular signaling, particularly in the regulation of inflammation and immune responses. The discovery of N-glycans as potential drug targets has led to a new era of drug development, with many companies investing in research and development of N-glycans-based therapeutics.

NBPF9 is one of these N-glycans that has generated significant interest due to its unique properties. NBPF9 is a glycosylated protein that is expressed in various tissues and cells, including the brain, pancreas, and gastrointestinal tract. It is composed of two main subunits, a N-terminal glycosylated fragment (N-GF) and a C-terminal glycosylated fragment (C-GF). N-GF is a glycophospholipid that contains a phosphate group, which is a common structural unit in many lipids. C-GF is a glycosylated glycoprotein that contains a glycophospholipid tail and a transmembrane region.

The unique feature of NBPF9 is its ability to interact with various N-glycans, including N-glycans on cancer cells and auto-antibodies. This interaction between NBPF9 and N-glycans has led to the potential implications for cancer and autoimmune diseases. NBPF9 has also been shown to interact with carbohydrates in the gut microbiome, which may have implications for gut health and disease.

The potential drug target for NBPF9 is its ability to modulate the activity of cancer cells and auto-antibodies. Cancer cells are known to have aberrant levels of N-glycans, which can contribute to their malignant behavior. By interacting with N-glycans on cancer cells, NBPF9 has the potential to inhibit cell signaling pathways that promote cancer growth and progression. Similarly, auto-antibodies are known to have impaired immune responses in diseases such as rheumatoid arthritis and systemic lupus erythematosus. By interacting with N-glycans on auto-antibodies, NBPF9 has the potential to enhance immune responses and improve disease management.

The discovery of NBPF9 also has the potential to impact the development of new diagnostic tests for cancer and auto-antibodies. The ability of NBPF9 to interact with N-glycans has led to the development of N-glycan-based biomarkers that can be used for non-invasive diagnostic assays. For example, NBPF9 has been shown to be expressed in various tissues and cells, including cancer cells and auto-antibodies. By detecting the levels of NBPF9 in these samples, diagnostic tests can accurately determine the presence or absence of cancer cells or auto-antibodies, with potential implications for early disease detection and personalized medicine.

In conclusion, NBPF9 is a unique N-glyc谩n that has the potential to impact drug development and diagnostic tests for cancer and auto-antibodies. Its ability to interact with N-glycans has led to its potential as a drug target and biomarker

Protein Name: NBPF Member 9

The "NBPF9 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NBPF9 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets